Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00053105 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | TheradexINDUSTRY | 1 | Jul 7, 2009 | clinicaltrials |
| NCT00004086 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 |
| Jun 9, 2009 |
| clinicaltrials |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | terminated | Phase 1 | 15 | BiogenINDUSTRY | 1 | Jun 5, 2009 | clinicaltrials |
| NCT00113724 | Study of TPI 287 in Patients With Advanced Malignancies | completed | Phase 1 | 48 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00070083 | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | completed | Phase 1 | — | British Columbia Cancer AgencyOTHER | 2 | Apr 7, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00452257 | A Study of Enzastaurin in Patients With Leukemia | completed | Phase 1 | 18 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 19, 2009 | clinicaltrials |
| NCT00533728 | Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | Biotec Pharmacon ASAINDUSTRY | 1 | Mar 4, 2009 | clinicaltrials |
| NCT00043420 | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00821301 | Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma | unknown | Phase 1 | 30 | Immune ControlINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00807196 | Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 20 | Maisonneuve-Rosemont HospitalOTHER | 1 | Dec 11, 2008 | clinicaltrials |
| NCT00088101 | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors | completed | Phase 1 | 42 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Dec 4, 2008 | clinicaltrials |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | completed | Phase 1 | 4 | Memgen, LLCINDUSTRY | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | completed | Phase 1 | 21 | Agenus Inc.INDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | completed | Phase 1 | 9 | Memgen, LLCINDUSTRY | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00161590 | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma | completed | Phase 1 | — | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 22, 2008 | clinicaltrials |
| NCT00085904 | Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Oct 13, 2008 | clinicaltrials |
| NCT00222443 | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | completed | Phase 1 | 40 | University of OklahomaOTHER | 1 | Sep 22, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00347971 | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | completed | Phase 1 | 23 | ZymoGeneticsINDUSTRY | 1 | Sep 5, 2008 | clinicaltrials |
| NCT00538096 | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | withdrawn | Phase 1 | 18 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00147485 | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | terminated | Phase 1 | — | ExelixisINDUSTRY | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00363610 | A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma | terminated | Phase 1 | 19 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00441818 | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 59 | TanoxINDUSTRY | 1 | May 9, 2008 | clinicaltrials |
| NCT00302861 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) | terminated | Phase 1 / Phase 2 | 86 | Genitope CorporationINDUSTRY | 0 | Mar 18, 2008 | clinicaltrials |
| NCT00001249 | Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001270 | Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma | completed | Phase 1 | 85 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001271 | A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001302 | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001333 | Phase I Study of Intrathecal Topotecan | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001444 | A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001689 | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | completed | Phase 1 | 90 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00077493 | BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | suspended | Phase 1 | 95 | MedImmune LLCINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00271063 | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 34 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 24 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00256191 | Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies | completed | Phase 1 | 45 | Cortice Biosciences, Inc.INDUSTRY | 1 | Oct 15, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jul 7, 2009source: clinicaltrials